Biopharmaceutics deal

BPII (Bellport, NY) acquired exclusive rights to a non-invasive diagnostic for Alzheimer's disease from the Cornell Research Foundation. The skin biopsy test detects high levels of the A-68 protein antigen in Alzheimer's patients' cultures. ...